

Media Contact
Vicky Tsami
(+30) 210-8930215

PRESS RELEASE

Athens, November 7th 2023 – Gilead Sciences Greece regrets to announce the suspension of the annual call for interest program for the provision of financial donations "ASKLEPIOS".

At Gilead, we're committed to creating a healthier world for everyone—no matter the challenges we face. In this light and in the context of its social role, Gilead Sciences Greece instituted in 2013, the pioneering program "ASKLEPIOS". The exclusive purpose of the program has been the support of independent research and education, as well as the general provision of better health services, succeeding in producing substantial and measurable results that were reflected in a multitude of announcements, both in Greek and international conferences and in articles published in international scientific journals (peer reviewed journals). It is noteworthy that, through the program, more than 140 basic research proposals as well as community actions were supported, with a total amount exceeding 1,800,000 euros.

During all these years of operation of "ASKLEPIOS", the drawn up procedures for ensuring transparency were strictly adhered to, with the main safety net being the assignment of the evaluation and grading of the submitted proposals to independent - third - to the company persons of recognized prestige in our country and internationally (Academic Advisors).

In an environment long hostile and 'punitive' to innovation, the continuation of such a program is now becoming incompatible and - currently - impossible. With the amount of mandatory returns (clawback) requested reaching 70%, it is clear that the institutional framework and applied policies have a catalytic effect on the wider planning, but possibly also on the long-term sustainability of Gilead Sciences Greece. By extension, they undermine any development initiative and could in the long term possibly deprive patients of the possibility of accessing new, innovative treatment regimens. Gilead Sciences Greece hopes that the appropriate conditions will soon be established and will allow the restart of "ASKLEPIOS", for the benefit of scientific progress.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. For more information, please send an email to GR-MEDICAL@gilead.com or call +30 210 8930100.